AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+0.92%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$640M
AUM Growth
+$640M
(-0.69%)
Cap. Flow
+$2.06M
Cap. Flow
% of AUM
0.32%
Top 10 Holdings %
Top 10 Hldgs %
47.48%
Holding
103
New
14
Increased
22
Reduced
20
Closed
16
Top Buys
| 1 |
Apogee Therapeutics
APGE
|
$12.1M |
| 2 |
Merus
MRUS
|
$9.57M |
| 3 |
Arvinas
ARVN
|
$7.76M |
| 4 |
Spyre Therapeutics
SYRE
|
$7.59M |
| 5 |
ProQR Therapeutics
PRQR
|
$7.49M |
Top Sells
| 1 |
Kezar Life Sciences
KZR
|
$15.9M |
| 2 |
Kura Oncology
KURA
|
$13.4M |
| 3 |
Astria Therapeutics
ATXS
|
$7.98M |
| 4 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$7.86M |
| 5 |
Viridian Therapeutics
VRDN
|
$7M |
Sector Composition
| 1 | Healthcare | 90.96% |
| 2 | Financials | 0.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Xenon Pharmaceuticals
XENE
$2.98B
| $45.5M | 6.1% | 1,161,237 +17,216 | +2% | +$675K |
|
|
2
Apogee Therapeutics
APGE
$2.17B
| $42.2M | 5.66% | 931,728 +267,530 | +40% | +$12.1M |
|
3
Arcellx
ACLX
$3.85B
| $32.6M | 4.37% | 425,000 +25,000 | +6% | +$1.92M |
|
4
Alkermes
ALKS
$4.78B
| $31.6M | 4.24% | 1,100,000 +100,000 | +10% | +$2.88M |
|
5
Teva Pharmaceuticals
TEVA
$21.1B
| $30.9M | 4.14% | 1,400,000 | – | – |
|
|
VRNA
6
Verona Pharma
VRNA
$9.16B
| $30.7M | 4.11% | 660,000 +10,000 | +2% | +$464K |
|
7
Madrigal Pharmaceuticals
MDGL
$9.76B
| $25.5M | 3.41% | 82,500 -17,500 | -18% | -$5.4M |
|
8
Crinetics Pharmaceuticals
CRNX
$2.92B
| $23.5M | 3.15% | 460,000 +60,000 | +15% | +$3.07M |
|
9
Nuvalent
NUVL
$5.52B
| $22.3M | 2.99% | 285,000 -52,500 | -16% | -$4.11M |
|
|
10
Spyre Therapeutics
SYRE
$996M
| $19.2M | 2.57% | 824,328 +325,908 | +65% | +$7.59M |
|
11
Wave Life Sciences
WVE
$1.53B
| $18.6M | 2.49% | 1,500,000 +100,000 | +7% | +$1.24M |
|
|
CNTA
12
Centessa Pharmaceuticals
CNTA
$2.25B
| $18.4M | 2.46% | 1,095,924 +130,312 | +13% | +$2.18M |
|
13
Vera Therapeutics
VERA
$1.38B
| $18M | 2.41% | 425,000 -10,000 | -2% | -$423K |
|
14
Nurix Therapeutics
NRIX
$714M
| $17.7M | 2.37% | 940,083 +79,684 | +9% | +$1.5M |
|
|
15
Merus
MRUS
$4.98B
| $16.4M | 2.19% | 389,241 +227,500 | +141% | +$9.57M |
|
16
Establishment Labs
ESTA
$1.2B
| $12.9M | 1.73% | 279,445 -11,002 | -4% | -$507K |
|
|
17
Arvinas
ARVN
$568M
| $12.1M | 1.62% | 630,000 +405,000 | +180% | +$7.76M |
|
|
INZY
18
DELISTED
Inozyme Pharma
INZY
| $11M | 1.47% | 3,972,318 +1,150,000 | +41% | +$3.19M |
|
19
NewAmsterdam Pharma
NAMS
$2.71B
| $10.9M | 1.46% | 425,000 -47,390 | -10% | -$1.22M |
|
|
AUTL
20
Autolus Therapeutics
AUTL
$399M
| $10.6M | 1.42% | 4,500,000 | – | – |
|
21
Geron
GERN
$893M
| $7.97M | 1.07% | 2,250,000 +750,000 | +50% | +$2.66M |
|
22
Rezolute
RZLT
$619M
| $7.72M | 1.03% | 1,575,000 -125,000 | -7% | -$613K |
|
|
23
ProQR Therapeutics
PRQR
$237M
| $7.49M | 1% | +2,825,000 | New | +$7.49M |
|
|
ORKA
24
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $7.15M | 0.96% | 368,698 +18,862 | +5% | +$366K |
|
25
Axsome Therapeutics
AXSM
$6.05B
| $6.35M | 0.85% | 75,000 -5,000 | -6% | -$423K |
|